| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.69 [0.56, 0.86] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | crucial | - |
| deaths (OS) (extension) | 0.76 [0.63, 0.92] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.54 [0.45, 0.64] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.62 [0.52, 0.74] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| DCR | 1.85 [1.35, 2.54] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 7.46 [2.53, 21.97] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 13.83 [6.28, 30.48] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 3.85 [2.72, 5.44] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 4.03 [0.18, 89.68] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 93.23 [5.71, 1522.42] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.55 [1.09, 2.21] | | < 1 | | 0% | 1 study (1/-) | 0.8 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 68.24 [4.16, 1120.28] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 290.72 [105.09, 804.24] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 133.97 [8.24, 2178.15] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 73.11 [4.46, 1198.64] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Arthritis TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 4.03 [0.18, 89.68] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 20.63 [1.20, 354.60] | | < 1 | | 0% | 1 study (1/-) | 2.0 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 6.06 [0.30, 121.47] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 4.03 [0.18, 89.68] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.00 [0.02, 50.69] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 1.32 [0.57, 3.04] | | < 1 | | 0% | 1 study (1/-) | 26.1 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 4.03 [0.18, 89.68] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.12 [0.01, 2.36] | | < 1 | | 0% | 1 study (1/-) | 91.5 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.50 [0.15, 1.66] | | < 1 | | 0% | 1 study (1/-) | 87.2 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 4.03 [0.18, 89.68] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.50 [0.05, 5.54] | | < 1 | | 0% | 1 study (1/-) | 71.2 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 2.01 [0.18, 22.29] | | < 1 | | 0% | 1 study (1/-) | 28.6 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 3.04 [0.61, 15.19] | | < 1 | | 0% | 1 study (1/-) | 8.8 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Infusion-related reaction AE (grade 3-4) | 6.06 [0.30, 121.47] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.50 [0.05, 5.54] | | < 1 | | 0% | 1 study (1/-) | 71.2 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 2.01 [0.07, 60.08] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 2.02 [0.37, 11.09] | | < 1 | | 0% | 1 study (1/-) | 21.1 % | NA | not evaluable | | non important | - |
